972 filings
Page 6 of 49
8-K
ACER
Acer Therapeutics Inc.
28 Jul 22
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
9:00am
8-K
ACER
Acer Therapeutics Inc.
18 Jul 22
Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs
8:45am
8-K
ACER
Acer Therapeutics Inc.
29 Jun 22
Regulation FD Disclosure
9:03am
8-K
ACER
Acer Therapeutics Inc.
27 Jun 22
Other Events
9:00am
4
Tanya Hayden
22 Jun 22
Acer Therapeutics / Tanya Hayden ownership change
4:06pm
3
Tanya Hayden
22 Jun 22
Acer Therapeutics / Tanya Hayden ownership change
4:04pm
8-K
ACER
Acer Therapeutics Inc.
21 Jun 22
Acer Therapeutics Announces Promotion of Tanya Hayden to Chief Operating Officer
8:37am
8-K
ACER
Acer Therapeutics Inc.
7 Jun 22
Acer Therapeutics Issues Statement Regarding PDUFA Target Action Date for ACER-001
9:00am
8-K
ACER
Acer Therapeutics Inc.
31 May 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:04pm
8-K
ACER
Acer Therapeutics Inc.
23 May 22
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
ACER
Acer Therapeutics Inc.
17 May 22
Other Events
4:21pm
424B2
ACER
Acer Therapeutics Inc.
17 May 22
Prospectus for primary offering
4:12pm
10-Q
2022 Q1
ACER
Acer Therapeutics Inc.
Quarterly report
16 May 22
4:19pm
8-K
ACER
Acer Therapeutics Inc.
16 May 22
Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update
12:00am
8-K
ACER
Acer Therapeutics Inc.
9 May 22
Phase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022
9:01am
8-K
ACER
Acer Therapeutics Inc.
6 May 22
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
9:00am
424B3
ACER
Acer Therapeutics Inc.
3 May 22
Prospectus supplement
4:01pm
EFFECT
ACER
Acer Therapeutics Inc.
3 May 22
Notice of effectiveness
12:15am
S-3/A
ACER
Acer Therapeutics Inc.
Shelf registration (amended)
28 Apr 22
5:01pm
CORRESP
ACER
Acer Therapeutics Inc.
28 Apr 22
Correspondence with SEC
12:00am